Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation
Experimental and Therapeutic Medicine · 15.02.2024 · 27 (4)
DOI: 10.3892/etm.2024.12430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 15.02.2024. Verfasst von Linfeng Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Zitieren
APA
Zheng, L., Mei, W., Zhou, J., Wei, X., Huang, Z., Lin, X., Zhang, L., Liu, W., Wu, Q., Li, J., & Yan, Y. (2024). Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation. Experimental and Therapeutic Medicine, 27(4). https://doi.org/10.3892/etm.2024.12430
Vancouver
Zheng L, Mei W, Zhou J, Wei X, Huang Z, Lin X, et al. Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation. Experimental and Therapeutic Medicine. 2024;27(4). doi:10.3892/etm.2024.12430
BibTeX
@article{Zheng2024,
author = {Zheng, Linfeng and Mei, Wenjuan and Zhou, Jing and Wei, Xin and Huang, Zhijuan and Lin, Xiaozhen and Zhang, Li and Liu, Wei and Wu, Qian and Li, Jinhong and Yan, Yan},
title = {Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation},
journal = {Experimental and Therapeutic Medicine},
year = {2024},
volume = {27},
number = {4},
doi = {10.3892/etm.2024.12430}
}
EUVIMED